更多开发者作品
The Lancet Haematology
| 1. | [Comment] Time to optimise management of haemolytic disease of the fetus and newborn | Jennifer Andrews, Matthew R Grace | |
| 2. | [Articles] Variations in antenatal management and outcomes in haemolytic disease of the fetus and newborn: an international, retrospective, observational cohort study | Derek P de Winter, Enrico Lopriore, Emilie Thorup, Olav Bjørn Petersen, Morten H Dziegiel, Karin Sundberg, Roland Devlieger, Luc de Catte, Liesbeth Lewi, Anne Debeer, Véronique Houfflin-Debarge, Louise Ghesquiere, Charles Garabedian, Kévin Le Duc, Eugenia Antolin, Nieves Mendez, James Castleman, Wing Ting Tse, Jean-Marie Jouannic, Paul Maurice, Jane Currie, Emma Mullen, Lut Geerts, Kerry Rademan, Asma Khalil, Borna Poljak, Smriti Prasad, Eleonor Tiblad, Kajsa Bohlin, Annegret Geipel, Johanna Rath, Fergal Malone, David Mackin, Yoav Yinon, Stav Cohen, Greg Ryan, Evangelia Vlachodimitropoulou, Karl-Philipp Gloning, Stefan Verlohren, Beate Mayer, Mariano Lanna, Stefano Faiola, Tanja Premru Sršen, Lilijana Kornhauser Cerar, Saul Snowise, Luming Sun, Lucas Otaño, César Hernan Meller, Ngina K Connors, Matthew Saxonhouse, Aline Wolter, Ivonne Bedei, Philipp Klaritsch, Sarah Jauch, Eduardo Teixeira da Silva Ribeiro, Fernando Maia Peixoto Filho, Raigam Jafet Martinez-Portilla, Alexandra Matias, Obdulia Alejos Abad, Juan Parra Roca, Ángel Guillermo Alcázar Grisi, Edgar Juan José Chávez Navarro, Johanna G van der Bom, Masja de Haas, EJT (Joanne) Verweij, DIONYSUS investigators | |
| 3. | [Articles] Concizumab prophylaxis in people with haemophilia A or haemophilia B without inhibitors (explorer8): a prospective, multicentre, open-label, randomised, phase 3a trial | Pratima Chowdary, Pantep Angchaisuksiri, Shashikant Apte, Jan Astermark, Gary Benson, Anthony K C Chan, Victor Jiménez Yuste, Tadashi Matsushita, Amalie Rhode Høgh Nielsen, Jameela Sathar, Christopher Sutton, Sonata Šaulytė Trakymienė, Huyen Tran, Laura Villarreal Martinez, Allison P Wheeler, Jerzy Windyga, Guy Young, Jay Jay Thaung Zaw, Hermann Eichler | |
| 4. | [Review] Accelerating and optimising CAR T-cell manufacture to deliver better patient products | Giulia Agliardi, Juliana Dias, Alexandros Rampotas, John Garcia, Claire Roddie | |
| 5. | [Corrections] Correction to Lancet Haematol 2024; 11: e862–72 | | |
| 6. | [Corrections] Correction to Lancet Haematol 2024; 11: e830–38 | | |
| 7. | [Corrections] Correction to Lancet Haematol 2024; 11: e580–92 | | |
| 8. | [Review] Changes in the landscape of anticoagulation: a focus on direct oral anticoagulants | Walter Ageno, Bruno Caramelli, Marco Paolo Donadini, Laura Girardi, Nicoletta Riva | |
| 9. | [In Focus] The story of my zebra | Ariana Mihan | |
| 10. | [Viewpoint] Radiation target nomenclature for lymphoma trials: consensus recommendations from the National Clinical Trials Network groups | Omran Saifi, Chelsea C Pinnix, Leslie K Ballas, Chris R Kelsey, Sarah A Milgrom, Stephanie A Terezakis, Nicholas B Figura, Rahul R Parikh, John C Grecula, Stella Flampouri, Chul S Ha, Andrea C Lo, John P Plastaras, David C Hodgson, Bradford S Hoppe | |
更新于 6 分钟前
近期历史最近 100 条记录
| 2024-11-09 | [Comment] Time to optimise management of haemolytic disease of the fetus and newborn | Jennifer Andrews, Matthew R Grace | |
| 2024-11-09 | [Articles] Variations in antenatal management and outcomes in haemolytic disease of the fetus and newborn: an international, retrospective, observational cohort study | Derek P de Winter, Enrico Lopriore, Emilie Thorup, Olav Bjørn Petersen, Morten H Dziegiel, Karin Sundberg, Roland Devlieger, Luc de Catte, Liesbeth Lewi, Anne Debeer, Véronique Houfflin-Debarge, Louise Ghesquiere, Charles Garabedian, Kévin Le Duc, Eugenia | |
| 2024-11-07 | [Articles] Concizumab prophylaxis in people with haemophilia A or haemophilia B without inhibitors (explorer8): a prospective, multicentre, open-label, randomised, phase 3a trial | Pratima Chowdary, Pantep Angchaisuksiri, Shashikant Apte, Jan Astermark, Gary Benson, Anthony K C Chan, Victor Jiménez Yuste, Tadashi Matsushita, Amalie Rhode Høgh Nielsen, Jameela Sathar, Christopher Sutton, Sonata Šaulytė Trakymienė, Huyen Tran, Laura V | |
| 2024-11-05 | [Review] Accelerating and optimising CAR T-cell manufacture to deliver better patient products | Giulia Agliardi, Juliana Dias, Alexandros Rampotas, John Garcia, Claire Roddie | |
| 2024-10-31 | [Corrections] Correction to Lancet Haematol 2024; 11: e862–72 | | |
| 2024-10-31 | [Corrections] Correction to Lancet Haematol 2024; 11: e830–38 | | |
| 2024-10-25 | [Corrections] Correction to Lancet Haematol 2024; 11: e580–92 | | |
| 2024-10-19 | [Review] Changes in the landscape of anticoagulation: a focus on direct oral anticoagulants | Walter Ageno, Bruno Caramelli, Marco Paolo Donadini, Laura Girardi, Nicoletta Riva | |
| 2024-10-09 | [Review] Data-driven, harmonised classification system for myelodysplastic syndromes: a consensus paper from the International Consortium for Myelodysplastic Syndromes | Rami S Komrokji, Luca Lanino, Somedeb Ball, Jan P Bewersdorf, Monia Marchetti, Giulia Maggioni, Erica Travaglino, Najla H Al Ali, Pierre Fenaux, Uwe Platzbecker, Valeria Santini, Maria Diez-Campelo, Avani Singh, Akriti G Jain, Luis E Aguirre, Sarah M Tins | |
| 2024-10-08 | [Comment] Balancing the dual challenge of cancer and pregnancy: insights from large-scale data | Pietro R Di Ciaccio, Georgia S Mills | |
| 2024-10-08 | [Articles] Maternal and obstetric outcomes in women with pregnancy-associated haematological malignancies: an observational nationwide cohort study | Pierre Pinson, Ismael Boussaid, Justine Decroocq, Laurent Chouchana, Gary Birsen, Mathilde Barrois, Vassilis Tsatsaris, Charlotte Godeberge, Jeremie Zerbit, Barbara Burroni, Frederic Pene, Laurence Huynh, Caroline Charlier, Jerome Tamburini, Nathanael Bee | |
| 2024-10-04 | [Comment] The Global Fund should extend its mandate to include universal access to hydroxyurea | Isaac Odame, Lêon Tshilolo, Julie Makani, Obiageli Nnodu, Adekunle Adekile, Baba Inusa | |
| 2024-10-04 | [In Focus] The story of my zebra | Ariana Mihan | |
| 2024-10-02 | [In Focus] Oh no, the light chain ratio | Christopher Tiplady | |
| 2024-10-01 | [Viewpoint] Radiation target nomenclature for lymphoma trials: consensus recommendations from the National Clinical Trials Network groups | Omran Saifi, Chelsea C Pinnix, Leslie K Ballas, Chris R Kelsey, Sarah A Milgrom, Stephanie A Terezakis, Nicholas B Figura, Rahul R Parikh, John C Grecula, Stella Flampouri, Chul S Ha, Andrea C Lo, John P Plastaras, David C Hodgson, Bradford S Hoppe | |
| 2024-09-21 | [Articles] Venetoclax plus decitabine as a bridge to allogeneic haematopoietic stem-cell transplantation in older patients with acute myeloid leukaemia (VEN-DEC GITMO): final report of a multicentre, single-arm, phase 2 trial | Domenico Russo, Nicola Polverelli, Simona Bernardi, Stella Santarone, Mirko Farina, Erika Borlenghi, Francesco Onida, Luca Castagna, Stefania Bramanti, Angelo Michele Carella, Roberto Sorasio, Massimo Martino, Caterina Alati, Attilio Olivieri, Germana Bel | |
| 2024-09-21 | [Comment] Transplantation and long-term overall survival in acute myeloid leukaemia | Maria A Perusini, Karen W L Yee | |
| 2024-09-20 | [Series] Sexual health and emotional wellbeing of patients with haematological malignancies: general review | Tamim Alsuliman, Reyes María Martín Rojas, Nour Moukalled, Eolia Brissot, Laurence Quarez-Blaise, Zora Marjanovic, Didier Blaise, Danielle Murphy, Melissa Logue, Bipin N Savani, Mohamad Mohty | |
| 2024-09-20 | [Comment] Sexual health and emotional wellbeing of adolescent and young adult survivors of haematological malignancies | Tamim Alsuliman, Reyes María Martín Rojas, Ahmad Ali Basha, Paolo Musiu, Léonardo Magro, Anna Maria Testi, Mohamad Mohty | |
| 2024-09-20 | [Series] Sexual health-related psychological and emotional life after allogeneic haematopoietic stem-cell transplantation | Tamim Alsuliman, Lugien Alasadi, Alice Polomeni, Antoine Capes, Zinaida Peric, Andrea Linke, Hélène Schoemans, Florent Malard, Yves Chalandon, Mohamad Mohty | |
| 2024-09-20 | [Series] Sexually transmitted infections in the context of haematological malignancies | Tamim Alsuliman, Paolo Musiu, Nicolas Stocker, Lana Desnica, Jean El-Cheikh, Simona Sestili, Micha Srour, Zora Marjanovic, Ali Alrstom | |
| 2024-09-20 | [In Focus] Let's talk about sex and haematopoietic stem-cell transplantation | Andrea Linke, Jacqueline del Castillo, Kirsti Scheffel, Peter Feenstra, Riikka-Leena Manninen | |
| 2024-09-18 | [Articles] Decitabine, venetoclax, and ponatinib for advanced phase chronic myeloid leukaemia and Philadelphia chromosome-positive acute myeloid leukaemia: a single-arm, single-centre phase 2 trial | Nicholas J Short, Daniel Nguyen, Elias Jabbour, Jayastu Senapati, Zhihong Zeng, Ghayas C Issa, Hussein Abbas, Cedric Nasnas, Wei Qiao, Xuelin Huang, Gautam Borthakur, Kelly Chien, Fadi G Haddad, Naveen Pemmaraju, Omer S Karrar, Danielle Nguyen, Marina Kon | |
| 2024-09-18 | [Comment] Triplet therapy for advanced BCR::ABL1 positive myeloid leukaemias | Mhairi Copland | |
| 2024-09-10 | [Articles] Efficacy and safety of fedratinib in patients with myelofibrosis previously treated with ruxolitinib (FREEDOM2): results from a multicentre, open-label, randomised, controlled, phase 3 trial | Claire N Harrison, Ruben Mesa, Moshe Talpaz, Haifa Kathrin Al-Ali, Blanca Xicoy, Francesco Passamonti, Francesca Palandri, Giulia Benevolo, Alessandro Maria Vannucchi, Clemence Mediavilla, Alessandra Iurlo, InHo Kim, Shelonitda Rose, Patrick Brown, Christ | |
| 2024-09-07 | [Articles] Ixazomib as consolidation and maintenance versus observation in patients with relapsed multiple myeloma eligible for salvage autologous stem-cell transplantation (Myeloma XII [ACCoRD]): interim analysis of a multicentre, open-label, randomised, | Gordon Cook, A John Ashcroft, Ethan Senior, Catherine Olivier, Anna Hockaday, Jeanine Richards, Jamie D Cavenagh, John A Snowden, Mark T Drayson, Ruth de Tute, Lesley Roberts, Roger G Owen, Kwee Yong, Mamta Garg, Kevin Boyd, Hamdi Sati, Sharon Gillson, Ma | |
| 2024-09-07 | [Comment] Continued need for autologous transplantation in relapsed myeloma | Elias K Mai | |
| 2024-08-31 | [Articles] Leukaemia, lymphoma, and multiple myeloma mortality after low-level exposure to ionising radiation in nuclear workers (INWORKS): updated findings from an international cohort study | Klervi Leuraud, Dominique Laurier, Michael Gillies, Richard Haylock, Kaitlin Kelly-Reif, Stephen Bertke, Robert D Daniels, Isabelle Thierry-Chef, Monika Moissonnier, Ausrele Kesminiene, Mary K Schubauer-Berigan, David B Richardson | |
| 2024-08-27 | [Viewpoint] Management of pregnancies with anti-K alloantibodies and the predictive value of anti-K titration testing | Evangelia Vlachodimitropoulou, Nadine Shehata, Greg Ryan, Gwen Clarke, Lani Lieberman | |
| 2024-08-13 | [Corrections] Correction to Lancet Haematol 2024; 10: e879–89 | | |
| 2024-08-06 | [Comment] Risk of harm to people with haemophilia from the 2023 WHO Essential Medicines List | Glenn F Pierce, Brian O'Mahony, Radoslaw Kaczmarek, Mark W Skinner, Mike Makris, Flora Peyvandi, Alok Srivastava, Cedric Hermans, World Federation of Hemophilia Coagulation Products Supply, Safety, and Access Committee (CPSSAC) | |
| 2024-07-25 | [Articles] Isatuximab plus carfilzomib–dexamethasone versus carfilzomib–dexamethasone in patients with relapsed multiple myeloma (IKEMA): overall survival analysis of a phase 3, randomised, controlled trial | Kwee Yong, Thomas Martin, Meletios-Athanasios Dimopoulos, Joseph Mikhael, Marcelo Capra, Thierry Facon, Roman Hajek, Ivan Špička, Ross Baker, Kihyun Kim, Gracia Martinez, Chang-Ki Min, Ludek Pour, Xavier Leleu, Albert Oriol, Youngil Koh, Kenshi Suzuki, Fr | |
| 2024-07-25 | [Comment] Isatuximab plus carfilzomib–dexamethasone for relapsed multiple myeloma | Dai Maruyama, Nobuhiko Yamauchi | |
| 2024-07-25 | [Comment] Etoposide addition and brentuximab vedotin consolidation in first-line treatment of CD30-positive peripheral T-cell lymphoma: can we improve BV–CHP? | Edith Julia, Emmanuel Bachy | |
| 2024-07-25 | [Articles] Brentuximab vedotin plus cyclophosphamide, doxorubicin, etoposide, and prednisone followed by brentuximab vedotin consolidation in CD30-positive peripheral T-cell lymphomas: a multicentre, single-arm, phase 2 study | Alex F Herrera, Jasmine Zain, Kerry J Savage, Tatyana Feldman, Jonathan E Brammer, Lu Chen, Sandrine Puverel, Leslie Popplewell, Lihua Elizabeth Budde, Matthew Mei, Chitra Hosing, Ranjit Nair, Lori Leslie, Shari Daniels, Lacolle Peters, Stephen Forman, St | |
| 2024-07-24 | [Comment] Anti-BCMA/GPRC5D bispecific CAR T cells for relapsed or refractory multiple myeloma: is 1 + 1 greater than 2? | Chenggong Li, Heng Mei | |
| 2024-07-24 | [Articles] Anti-BCMA/GPRC5D bispecific CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, single-centre, phase 1 trial | Dian Zhou, Qian Sun, Jieyun Xia, Weiying Gu, Jun Qian, Wanchuan Zhuang, Zhiling Yan, Hai Cheng, Wei Chen, Feng Zhu, Kunming Qi, Depeng Li, Wei Sang, Lili Zhu, Sha Ma, Hujun Li, Huanxin Zhang, Tingting Qiu, Dongmei Yan, Yanlei Zhang, Shuixiu Peng, Alex H C | |
| 2024-07-20 | [Articles] Luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): primary analysis of a phase 3, open-label, randomised, controlled trial | Matteo Giovanni Della Porta, Guillermo Garcia-Manero, Valeria Santini, Amer M Zeidan, Rami S Komrokji, Jake Shortt, David Valcárcel, Anna Jonasova, Sophie Dimicoli-Salazar, Ing Soo Tiong, Chien-Chin Lin, Jiahui Li, Jennie Zhang, Richard Pilot, Sandra Krei | |
| 2024-07-20 | [Comment] A stimulating advance in erythropoiesis for patients with myelodysplastic syndromes | Yazan F Madanat, Amy E DeZern | |
| 2024-07-19 | [Articles] Pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in patients with B-cell malignancies: analysis of the Richter transformation subgroup from the multicentre, open-label, phase 1/2 BRUIN study | William G Wierda, Nirav N Shah, Chan Y Cheah, David Lewis, Marc S Hoffmann, Catherine C Coombs, Nicole Lamanna, Shuo Ma, Deepa Jagadeesh, Talha Munir, Yucai Wang, Toby A Eyre, Joanna M Rhodes, Matthew McKinney, Ewa Lech-Maranda, Constantine S Tam, Wojciec | |
| 2024-07-19 | [Review] Mechanisms of resistance against T-cell engaging bispecific antibodies in multiple myeloma: implications for novel treatment strategies | Niels W C J van de Donk, Ajai Chari, Maria Victoria Mateos | |
| 2024-07-19 | [Articles] Low dose lenalidomide versus placebo in non-transfusion dependent patients with low risk, del(5q) myelodysplastic syndromes (SintraREV): a randomised, double-blind, phase 3 trial | María Díez-Campelo, Félix López-Cadenas, Blanca Xicoy, Eva Lumbreras, Teresa González, Mónica del Rey González, Joaquín Sánchez-García, Rosa Coll Jordà, Bohrane Slama, Jose-Ángel Hernández-Rivas, Sylvain Thepot, Teresa Bernal, Agnès Guerci-Bresler, Joan B | |
| 2024-07-19 | [Comment] Overcoming the unmet need of Richter transformation: the use of pirtobrutinib | Tamar Tadmor | |
| 2024-07-19 | [Comment] SintraREViewed: practice changing, or validation required? | Rena Buckstein | |
| 2024-07-12 | [Corrections] Correction to Lancet Haematol 2024; 11: e510–20 | | |
| 2024-07-11 | [Articles] Ruxolitinib in treatment-naive or corticosteroid-refractory paediatric patients with chronic graft-versus-host disease (REACH5): interim analysis of a single-arm, multicentre, phase 2 study | Franco Locatelli, Bulent Antmen, Hyoung Jin Kang, Katsuyoshi Koh, Yoshiyuki Takahashi, Alphan Kupesiz, Maria Gabriela A Dias Matos, Yogi Chopra, Sunil Bhat, Ho Joon Im, Tayfun Güngör, Meng-Yao Lu, Tommaso Stefanelli, Christine Rosko, Annie St Pierre, Kari | |
| 2024-07-11 | [Comment] Ruxolitinib: a game changer in paediatric chronic graft-versus-host disease management? | Luisa Sisinni | |
| 2024-07-05 | [News] European Hematology Association 2024 Hybrid Congress | Yaiza del Pozo Martín, Emma Cookson | |
| 2024-07-03 | [Review] Diagnosis and management of Evans syndrome in adults: first consensus recommendations | Bruno Fattizzo, Monia Marchetti, Marc Michel, Silvia Cantoni, Henrik Frederiksen, Giulio Giordano, Andreas Glenthøj, Tomás José González-López, Irina Murakhovskaya, Mariasanta Napolitano, Maria-Eva Mingot, Maria Arguello, Andrea Patriarca, Simona Raso, Ni | |
| 2024-07-02 | [Comment] Dismantling cost and infrastructure barriers to equitable access to gene therapies for sickle cell disease | Akshay Sharma, Tami D John | |
| 2024-06-15 | [Articles] Epcoritamab monotherapy in patients with relapsed or refractory follicular lymphoma (EPCORE NHL-1): a phase 2 cohort of a single-arm, multicentre study | Kim M Linton, Umberto Vitolo, Wojciech Jurczak, Pieternella J Lugtenburg, Emmanuel Gyan, Anna Sureda, Jacob Haaber Christensen, Brian Hess, Hervé Tilly, Raul Cordoba, David John Lewis, Craig Okada, Martin Hutchings, Michael Roost Clausen, Juan-Manuel Sanc | |
| 2024-06-14 | [Articles] Efficacy and safety of sovleplenib (HMPL-523) in adult patients with chronic primary immune thrombocytopenia in China (ESLIM-01): a randomised, double-blind, placebo-controlled, phase 3 study | Yu Hu, Xiaofan Liu, Hu Zhou, Shujie Wang, Ruibin Huang, Yi Wang, Xin Du, Jing Sun, Zeping Zhou, Zhenyu Yan, Wenming Chen, Wei Wang, Qingchi Liu, Qingshu Zeng, Yuping Gong, Jie Yin, Xuliang Shen, Baodong Ye, Yun Chen, Yajing Xu, Huiping Sun, Yunfeng Cheng, | |
| 2024-06-14 | [Comment] Sovleplenib in immune thrombocytopenia | María Eva Mingot-Castellano | |
| 2024-06-13 | [Articles] Thrombotic risk and features of patients with inferior vena cava agenesis: a multicentre, retrospective, observational study | Carlos Bravo-Pérez, Ana Blanco, Nuria Revilla, Jorge Cobos, Alba Salgado-Parente, Susana Asenjo, Ramiro Méndez, Luis Marti-Bonmati, Santiago Bonanad, José C Albillos, Nerea Castro, Shally Marcellini, Paul López Sala, Maialen Lasa, José M Bastida, María S | |
| 2024-06-13 | [Comment] Anticoagulation in patients with inferior vena cava agenesia | Rafael S Cires-Drouet | |
| 2024-06-08 | [Editorial] UK tainted blood: amplifying the voices of the victims | The Lancet Haematology | |
| 2024-06-08 | [News] Infected blood scandal linked to more than 3000 deaths | Elizabeth Gourd | |
| 2024-06-06 | [Corrections] Correction to Lancet Haematol 2024; 11: e310–11 | | |
| 2024-06-06 | [Corrections] Correction to Lancet Haematol 2024; 11: e459–70 | | |
| 2024-06-04 | [Articles] Response-adapted ultra-low-dose 4 Gy radiation as definitive therapy of gastric MALT lymphoma: a single-centre, pilot trial | Jillian R Gunther, Jie Xu, Manoop S Bhutani, Paolo Strati, Penny Q Fang, Susan Y Wu, Bouthaina S Dabaja, Wenli Dong, Priya R Bhosale, Christopher R Flowers, Ranjit Nair, Luis Malpica Castillo, Luis Fayad, Swaminathan P Iyer, Simrit Parmer, Michael Wang, H | |
| 2024-06-04 | [Comment] Ultra-low-dose radiation for gastric MALT lymphoma | Peter Meidahl Petersen, Dorte Schou Nørøxe | |
| 2024-05-31 | [Articles] Iadademstat in combination with azacitidine in patients with newly diagnosed acute myeloid leukaemia (ALICE): an open-label, phase 2a dose-finding study | Olga Salamero, Antonieta Molero, José Antonio Pérez-Simón, Montserrat Arnan, Rosa Coll, Sara Garcia-Avila, Evelyn Acuña-Cruz, Isabel Cano, Tim C P Somervaille, Sonia Gutierrez, María Isabel Arévalo, Jordi Xaus, Carlos Buesa, Ana Limón, Douglas V Faller, F | |
| 2024-05-24 | [Articles] Pembrolizumab and low-dose, single-fraction radiotherapy for patients with relapsed or refractory multiple myeloma: a prospective, single-centre, single-group, open-label, phase 2 pilot trial in the USA | Mohammad K Khan, Tahseen H Nasti, Joshua Y Qian, Troy J Kleber, Jeffrey M Switchenko, Jonathan L Kaufman, Ajay J Nooka, Madhav V Dhodapkar, Zachary S Buchwald, Daby Obiekwe, Sagar Lonial, Rafi Ahmed | |
| 2024-05-09 | [Review] Immune effector cell-associated haematotoxicity after CAR T-cell therapy: from mechanism to management | Kai Rejeski, Michael D Jain, Nirali N Shah, Miguel-Angel Perales, Marion Subklewe | |
| 2024-05-04 | [Articles] Garadacimab for hereditary angioedema attack prevention: long-term efficacy, quality of life, and safety data from a phase 2, randomised, open-label extension study | Timothy J Craig, Donald S Levy, Avner Reshef, William R Lumry, Inmaculada Martinez-Saguer, Joshua S Jacobs, William H Yang, Bruce Ritchie, Emel Aygören-Pürsün, Paul K Keith, Paula Busse, Henrike Feuersenger, Mihai Alexandru Bica, Iris Jacobs, Ingo Pragst, | |
| 2024-05-04 | [News] 50th Annual Meeting of the EBMT | Yaiza del Pozo Martín | |
| 2024-05-01 | [Articles] Hydroxyurea dose optimisation for children with sickle cell anaemia in sub-Saharan Africa (REACH): extended follow-up of a multicentre, open-label, phase 1/2 trial | Banu Aygun, Adam Lane, Luke R Smart, Brígida Santos, Léon Tshilolo, Thomas N Williams, Peter Olupot-Olupot, Susan E Stuber, George Tomlinson, Teresa Latham, Russell E Ware, REACH Investigators | |
| 2024-05-01 | [Comment] Long-term data from the REACH study testing hydroxyurea to treat sickle cell anaemia in children in sub-Saharan Africa | Najibah A Galadanci, Julie Kanter | |
| 2024-04-25 | [Articles] Isatuximab, carfilzomib, lenalidomide, and dexamethasone in patients with newly diagnosed, transplantation-eligible multiple myeloma (SKylaRk): a single-arm, phase 2 trial | Elizabeth O'Donnell, Clifton Mo, Andrew J Yee, Omar Nadeem, Jacob Laubach, Jacalyn Rosenblatt, Nikhil Munshi, Shonali Midha, Diana Cirstea, Pavlina Chrysafi, Nora Horick, Paul G Richardson, Noopur Raje | |
| 2024-04-25 | [Comment] Another quadruplet therapy for multiple myeloma: the beginning of the end for autologous haematopoietic stem-cell transplantation? | Natalie Scott Callander | |
| 2024-04-18 | [Corrections] Correction to Lancet Haematol 2024; 11: e27–37 | | |
| 2024-04-09 | [Viewpoint] Methodological challenges in the development of endpoints for myelofibrosis clinical trials | Giovanni Barosi, Ayalew Tefferi, Naseema Gangat, Natasha Szuber, Alessandro Rambaldi, Olatoyosi Odenike, Nicolaus Kröger, Nico Gagelmann, Moshe Talpaz, Hagop Kantarjian, Robert Peter Gale | |
| 2024-04-05 | [Articles] Remission induction versus immediate allogeneic haematopoietic stem cell transplantation for patients with relapsed or poor responsive acute myeloid leukaemia (ASAP): a randomised, open-label, phase 3, non-inferiority trial | Matthias Stelljes, Jan Moritz Middeke, Gesine Bug, Eva-Maria Wagner-Drouet, Lutz P Müller, Christoph Schmid, Stefan W Krause, Wolfgang Bethge, Edgar Jost, Uwe Platzbecker, Stefan A Klein, Jörg Schubert, Judith Niederland, Martin Kaufmann, Kerstin Schäfer- | |
| 2024-04-05 | [Comment] Transplant without salvage: cut out the middleman | Arjun Datt Law, Jonas Ingemar Mattsson | |
| 2024-03-29 | [Articles] Anti-CD30 CAR T cells as consolidation after autologous haematopoietic stem-cell transplantation in patients with high-risk CD30+ lymphoma: a phase 1 study | Natalie S Grover, George Hucks, Marcie L Riches, Anastasia Ivanova, Dominic T Moore, Thomas C Shea, Mary Beth Seegars, Paul M Armistead, Kimberly A Kasow, Anne W Beaven, Christopher Dittus, James M Coghill, Katarzyna J Jamieson, Benjamin G Vincent, Willia | |
| 2024-03-29 | [Comment] The value of anti-CD30 CAR T cells in Hodgkin lymphoma | Marianne Veyri | |
| 2024-03-28 | [Articles] Riociguat in patients with sickle cell disease and hypertension or proteinuria (STERIO-SCD): a randomised, double-blind, placebo controlled, phase 1–2 trial | Mark T Gladwin, Victor R Gordeuk, Payal C Desai, Caterina Minniti, Enrico M Novelli, Claudia R Morris, Kenneth I Ataga, Laura De Castro, Susanna A Curtis, Fuad El Rassi, Hubert James Ford, Thomas Harrington, Elizabeth S Klings, Sophie Lanzkron, Darla Lile | |
| 2024-03-28 | [Comment] Riociguat shows remarkable safety but underwhelming activity in patients with sickle cell disease | Emily M Limerick, Courtney D Fitzhugh | |
| 2024-03-28 | [Articles] First-line sintilimab with pegaspargase, gemcitabine, and oxaliplatin in advanced extranodal natural killer/T cell lymphoma (SPIRIT): a multicentre, single-arm, phase 2 trial | Xiao-Peng Tian, Jun Cai, Yi Xia, Yu-Chen Zhang, Liang Wang, Pan-Pan Liu, Hui-Qiang Huang, Ya-Jun Li, Hui Zhou, Zhi-Ming Li, Jing Yang, Li-Qiang Wei, Qi-Hua Zou, Ying Huang, Jun Li, Li Ling, Wen-Long Zhong, Qing-Qing Cai | |
| 2024-03-28 | [Comment] First-line immunochemotherapy for extranodal natural killer/T cell lymphoma | Shu-Nan Qi, Ye-Xiong Li | |
匿名用户只展示最新 100 条榜单历史，更多历史数据请登录后查看，支持时光机按天筛选
Sponsors
